TY - JOUR
T1 - Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
T2 - Guidelines from the International Lymphoma Radiation Oncology Group
AU - Ng, Andrea K
AU - Yahalom, Joachim
AU - Goda, Jayant S
AU - Constine, Louis S
AU - Pinnix, Chelsea C
AU - Kelsey, Chris R
AU - Hoppe, Bradford
AU - Oguchi, Masahiko
AU - Suh, Chang-Ok
AU - Wirth, Andrew
AU - Qi, Shunan
AU - Davies, Andrew
AU - Moskowitz, Craig H
AU - Laskar, Siddhartha
AU - Li, Yexiong
AU - Mauch, Peter M
AU - Specht, Lena
AU - Illidge, Timothy
N1 - Copyright © 2017 Elsevier Inc. All rights reserved.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.
AB - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Cyclophosphamide/administration & dosage
KW - Dose Fractionation, Radiation
KW - Doxorubicin/administration & dosage
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Lymphoma, Large B-Cell, Diffuse/diagnostic imaging
KW - Neoplasm, Residual
KW - Prednisone/administration & dosage
KW - Recurrence
KW - Rituximab/administration & dosage
KW - Salvage Therapy/methods
KW - Vincristine/administration & dosage
U2 - 10.1016/j.ijrobp.2017.12.005
DO - 10.1016/j.ijrobp.2017.12.005
M3 - Review
C2 - 29413279
SN - 0360-3016
VL - 100
SP - 652
EP - 669
JO - International Journal of Radiation Oncology, Biology, Physics
JF - International Journal of Radiation Oncology, Biology, Physics
IS - 3
ER -